Skip to content

NewAmsterdam Pharma Company NAMS Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Merck & Co. logo
Merck & Co.MRK
$157M+726%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$163.1M+169%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$12.37M

Other financials

Income statement

See full
Revenue$3.0M+2.1%
Operating income-$58.4M+15.2%
Net income-$48.4M-22.6%
EPS (diluted)-$0.40-17.6%

Balance sheet

See full
Cash & equivalents$457.6M-38.9%
Total debt$23.0K-94.1%
Total equity$665.2M-14.4%
Total assets$732.6M-10.5%

Cash flow

See full
Operating cash flow-$30.6M+16.1%
CapEx$38.0K+138%
Free cash flow-$30.6M+16.0%

Valuation

See full
Market cap$3.67B+63.7%

Profitability

See full
Operating margin-953.6%-3,536pp
Net margin-942.8%-3,477pp
FCF margin-630.1%-6,324pp

Returns & leverage

See full
Return on equity-29.5%-1.8pp
Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NewAmsterdam Pharma Company's stock issuance proceeds?
NewAmsterdam Pharma Company (NAMS) reported stock issuance proceeds of $10.41M in Q1 2026.
How has NewAmsterdam Pharma Company's stock issuance proceeds changed year-over-year?
NewAmsterdam Pharma Company's stock issuance proceeds increased by 31.5% year-over-year, from $7.92M to $10.41M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.